Prana Biotechnology EPS - Earnings per Share 2010-2021 | ATHE
Prana Biotechnology eps - earnings per share from 2010 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Prana Biotechnology Annual EPS |
2021 |
$-0.40 |
2020 |
$-0.60 |
2019 |
$-0.86 |
2018 |
$-0.72 |
2017 |
$-0.64 |
2016 |
$-0.64 |
2015 |
$-3.52 |
2014 |
$-1.74 |
2013 |
$-1.44 |
2012 |
$-1.14 |
2011 |
$-1.56 |
2010 |
$-1.14 |
2009 |
$-1.86 |
Prana Biotechnology Quarterly EPS |
2021-12-31 |
$0.00 |
2021-06-30 |
$0.00 |
2020-12-31 |
$0.00 |
2020-06-30 |
$0.00 |
2019-12-31 |
$0.00 |
2019-06-30 |
$0.00 |
2018-12-31 |
$0.00 |
2018-06-30 |
$0.00 |
2017-12-31 |
$0.00 |
2017-06-30 |
$0.00 |
2016-12-31 |
$0.00 |
2016-06-30 |
$0.00 |
2015-12-31 |
$0.00 |
2015-06-30 |
$0.00 |
2014-12-31 |
$0.00 |
2014-06-30 |
$0.00 |
2013-12-31 |
$0.00 |
2013-06-30 |
$0.00 |
2012-12-31 |
$0.00 |
2012-06-30 |
$0.00 |
2011-12-31 |
$0.00 |
2011-06-30 |
$0.00 |
2010-12-31 |
$0.00 |
2010-06-30 |
$0.00 |
2009-12-31 |
$0.00 |
2009-06-30 |
$0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.015B |
$0.003B |
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
|